150 related articles for article (PubMed ID: 24549164)
1. Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study.
Lexchin J
BMJ Open; 2014 Feb; 4(2):e004289. PubMed ID: 24549164
[TBL] [Abstract][Full Text] [Related]
2. Health Canada's use of its priority review process for new drugs: a cohort study.
Lexchin J
BMJ Open; 2015 May; 5(5):e006816. PubMed ID: 25967989
[TBL] [Abstract][Full Text] [Related]
3. How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009.
Lexchin J
Open Med; 2014; 8(1):e14-9. PubMed ID: 25009681
[TBL] [Abstract][Full Text] [Related]
4. Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010.
Downing NS; Shah ND; Aminawung JA; Pease AM; Zeitoun JD; Krumholz HM; Ross JS
JAMA; 2017 May; 317(18):1854-1863. PubMed ID: 28492899
[TBL] [Abstract][Full Text] [Related]
5. Post-market safety warnings for drugs approved in Canada under the Notice of Compliance with conditions policy.
Lexchin J
Br J Clin Pharmacol; 2015 May; 79(5):847-59. PubMed ID: 25393960
[TBL] [Abstract][Full Text] [Related]
6. Post-approval safety issues with innovative drugs: a European cohort study.
Mol PG; Arnardottir AH; Motola D; Vrijlandt PJ; Duijnhoven RG; Haaijer-Ruskamp FM; de Graeff PA; Denig P; Straus SM
Drug Saf; 2013 Nov; 36(11):1105-15. PubMed ID: 24048690
[TBL] [Abstract][Full Text] [Related]
7. Analysis of factors related to the occurrence of important drug-specific postmarketing safety-related regulatory actions: A cohort study focused on first-in-class drugs.
Ikeda J; Kaneko M; Narukawa M
Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1393-1401. PubMed ID: 30094880
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals.
Schick A; Miller KL; Lanthier M; Dal Pan G; Nardinelli C
Drug Saf; 2017 Jun; 40(6):497-503. PubMed ID: 28342075
[TBL] [Abstract][Full Text] [Related]
9. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):687-94. PubMed ID: 26554874
[TBL] [Abstract][Full Text] [Related]
10. How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study.
Lexchin J
Healthc Policy; 2016 Nov; 12(2):65-75. PubMed ID: 28032825
[TBL] [Abstract][Full Text] [Related]
11. Formulary status of drugs in Ontario after Health Canada has issued a serious safety warning: a cohort study.
Lexchin J
Int J Risk Saf Med; 2015; 27(3):135-42. PubMed ID: 26410247
[TBL] [Abstract][Full Text] [Related]
12. US Food and Drug Administration regulatory reviewer disagreements and postmarket safety actions among new therapeutics.
Eadie A; MacGregor A; Wallach J; Ross J; Herder M
BMJ Evid Based Med; 2023 Jun; 28(3):151-156. PubMed ID: 36944478
[TBL] [Abstract][Full Text] [Related]
13. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
Moore TJ; Furberg CD
JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
[TBL] [Abstract][Full Text] [Related]
14. Postmarket Safety Outcomes for New Molecular Entity (NME) Drugs Approved by the Food and Drug Administration Between 2002 and 2014.
Pinnow E; Amr S; Bentzen SM; Brajovic S; Hungerford L; St George DM; Dal Pan G
Clin Pharmacol Ther; 2018 Aug; 104(2):390-400. PubMed ID: 29266187
[TBL] [Abstract][Full Text] [Related]
15. Postmarket safety of drugs approved by Health Canada on the basis of clinical and surrogate outcomes: a cohort study.
Lexchin J; Ahmed T
CMAJ Open; 2015; 3(3):E286-91. PubMed ID: 26442227
[TBL] [Abstract][Full Text] [Related]
16. Drug Withdrawal Due to Safety: A Review of the Data Supporting Withdrawal Decision.
Craveiro NS; Lopes BS; Tomás L; Almeida SF
Curr Drug Saf; 2020; 15(1):4-12. PubMed ID: 31584381
[TBL] [Abstract][Full Text] [Related]
17. Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States.
Bhasale AL; Sarpatwari A; De Bruin ML; Lexchin J; Lopert R; Bahri P; Mintzes BJ
Clin Pharmacol Ther; 2021 Jun; 109(6):1424-1442. PubMed ID: 32767557
[TBL] [Abstract][Full Text] [Related]
18. A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.
Mol PG; Straus SM; Piening S; de Vries JT; de Graeff PA; Haaijer-Ruskamp FM
Drug Saf; 2010 Jun; 33(6):463-74. PubMed ID: 20486729
[TBL] [Abstract][Full Text] [Related]
19. New drug approval times and safety warnings in the United States and Canada, 1992-2011.
Rawson NS
J Popul Ther Clin Pharmacol; 2013; 20(2):e67-81. PubMed ID: 23650206
[TBL] [Abstract][Full Text] [Related]
20. An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making.
McNaughton R; Huet G; Shakir S
BMJ Open; 2014 Jan; 4(1):e004221. PubMed ID: 24435895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
